Interferon-complement loop in transplant-associated thrombotic microangiopathy

Abstract excerpt

Transplant-associated thrombotic microangiopathy (TA-TMA) is an important cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The complement inhibitor eculizumab improves TA-TMA, but not all patients respond to therapy, prompting a search for additional targetable pathways of endothelial injury. TA-TMA is relatively common after HSCT and can serve as a model to study mechanisms...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Complement system in diseases
• Share to Renal Diseases and Glomerulopathies
• Share to Renal Transplantation Outcomes and Treatments